Pharmafile Logo

Bayer

NICE publishes guidance recommending Bayer‪s Kerendia (finerenone) as an option for treating adult patients with chronic kidney disease associated with type 2 diabetes

Reading, 23rd March 2023 - Today, the National Institute for Health and Care Excellence (NICE) has published a new guidance (TA877) recommending the use of finerenone (10mg and 20mg) by NHS England as an option for treating chronic kidney disease (CKD) (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.1 Finerenone...

Bayer to manufacture mRNA vaccine in Germany

Berlin, Germany, February 1, 2021 - In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer of CureVac N.V., Franz-Werner Haas, Member of the Board of Management, Bayer AG and President of the Bayerís Pharmaceuticals Division, Stefan Oelrich, made the following statement:

CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV

Companies enter into a collaboration and services agreement / Bayer to support CureVac in numerous areas, including development and supply of CVnCoV / CureVac benefits from Bayer¥s expertise and established infrastructure / Plan to facilitate the supply of several hundred million doses
51368 Leverkusen

+49 214 30-1